VHH antibody partnerships

Harness the power of clinically accepted VHH antibodies to revolutionise your research. Accelerate your antibody discovery, enhance precision, and secure your innovations with Isogenica’s tailor-made solutions.

 

Unmatched diversity

With the world’s largest synthetic VHH libraries, Isogenica offers unparalleled diversity in antibody discovery. This extensive collection ensures that partners have access to a broad spectrum of high-affinity antibodies, increasing the chances of finding the perfect match for your therapeutic or diagnostic needs.

 

Risk reduction for long-term success

At Isogenica, we understand the high-stakes nature of early-stage drug discovery, often working with start-ups and other stealth-mode organisations. Our focus on risk reduction, coupled with our proven track record, makes us a reliable partner for those navigating complex development challenges. Isogenica’s solutions not only reduce development timelines but also enhance the likelihood of success by securing robust intellectual property early in the process. This strategic advantage ensures both immediate progress and long-term commercial viability.

 

Be part of the team

Our tailor-made approach to VHH antibody discovery extends to how we do business – working in different ways with different partners, big and small. This includes fee-for-service contracts, rolling FTE models, or success-based milestones depending on each partner’s needs.

Isogenica Funded Discovery Graphic

“It’s been a pleasure working with the Isogenica team. The regular project updates and open discussions ensured that together we could overcome the challenges presented by the biology of the targets and maximized our chances of success.”

Project Lead

Clinical-stage Biotech

Meet our partners

AstraZeneca

We have an ongoing research programme with AstraZeneca. The partnership centres around the use of our CIS display technology for the discovery of peptides which are specific for, and biologically active against, targets provided by AstraZeneca.

Read more here and find out about an example target, phospholamban.

Aro Biotherapeutics

Teaming up with Aro, we’re working with them using our CIS display to identify and characterise novel Centyrins™ against target antigens. Read more.

Axxam S.p.A

Our partnership with Axxam offers our clients the access to a broad portfolio of services to support their early-stage discovery of therapeutic antibodies, combining our VHH libraries with Axxam’s functional assay development (both cellular and in vitro) and cutting-edge high-throughput screening platforms.
Read more.

WellmarkerBio

Our partnership with WellmarkerBio and Isogenica involves the research and development of antibody-based cancer immunotherapy, Protein-Protein Interaction (PPI) Inhibitors, biomarkers and peptide libraries. Read more.

Takeda

Our partnership with Takeda sees them use our family of VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products. Read more.

Frederick National Laboratory for Cancer Research

Our multi-project contract is aiming to develop molecules that can be used in clinical laboratory assays to measure biomarkers correlated with the molecular effectiveness of cancer immuno-oncology agents. Read more.

Arvinas

We’ve teamed up with Arvinas who are leveraging our CIS display technology in support of advancing and expanding their PROTAC® platform. Read more.

Partnerships at Isogenica

Despite the confidentiality of our clients, Isogenica consistently receives high satisfaction ratings, with 100% of VHH discovery customers rating between 8 and 10/10 on how likely they would be to recommend our organization to a friend or colleague.

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including three clinical-stage assets (Phase I and Phase II) and dozens of partnered pre-clinical and discovery programs.

Contact us to find out how to revolutionise your research and development with VHH antibody technologies.

Contact us